Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews, T. V. Karpinets, P. A. Prieto, D. Vicente, K. Hoffman, S. C. Wei, A. P. Cogdill, L. Zhao, C. W. Hudgens, D. S. Hutchinson, T. Manzo, M. Petaccia De Macedo, T. Cotechini, T. Kumar, W. S. Chen, S. M. Reddy & 50 others R. Szczepaniak Sloane, J. Galloway-Pena, H. Jiang, P. L. Chen, E. J. Shpall, K. Rezvani, A. M. Alousi, R. F. Chemaly, S. Shelburne, L. M. Vence, P. C. Okhuysen, V. B. Jensen, A. G. Swennes, F. McAllister, E. Marcelo Riquelme Sanchez, Y. Zhang, E. Le Chatelier, L. Zitvogel, N. Pons, J. L. Austin-Breneman, L. E. Haydu, E. M. Burton, J. M. Gardner, E. Sirmans, J. Hu, A. J. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. C. Glitza, W. J. Hwu, S. P. Patel, S. E. Woodman, R. N. Amaria, M. A. Davies, J. E. Gershenwald, P. Hwu, J. E. Lee, J. Zhang, Lisa Coussens, Z. A. Cooper, P. A. Futreal, C. R. Daniel, N. J. Ajami, J. F. Petrosino, M. T. Tetzlaff, P. Sharma, J. P. Allison, R. R. Jenq, J. A. Wargo

Research output: Contribution to journalArticle

441 Citations (Scopus)

Abstract

Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalScience
Volume359
Issue number6371
DOIs
StatePublished - Jan 5 2018

Fingerprint

Immunotherapy
Melanoma
Programmed Cell Death 1 Receptor
Bacteria
Metagenomics
Gastrointestinal Microbiome
Microbiota
Immunity
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., ... Wargo, J. A. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97-103. https://doi.org/10.1126/science.aan4236

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. / Gopalakrishnan, V.; Spencer, C. N.; Nezi, L.; Reuben, A.; Andrews, M. C.; Karpinets, T. V.; Prieto, P. A.; Vicente, D.; Hoffman, K.; Wei, S. C.; Cogdill, A. P.; Zhao, L.; Hudgens, C. W.; Hutchinson, D. S.; Manzo, T.; Petaccia De Macedo, M.; Cotechini, T.; Kumar, T.; Chen, W. S.; Reddy, S. M.; Szczepaniak Sloane, R.; Galloway-Pena, J.; Jiang, H.; Chen, P. L.; Shpall, E. J.; Rezvani, K.; Alousi, A. M.; Chemaly, R. F.; Shelburne, S.; Vence, L. M.; Okhuysen, P. C.; Jensen, V. B.; Swennes, A. G.; McAllister, F.; Marcelo Riquelme Sanchez, E.; Zhang, Y.; Le Chatelier, E.; Zitvogel, L.; Pons, N.; Austin-Breneman, J. L.; Haydu, L. E.; Burton, E. M.; Gardner, J. M.; Sirmans, E.; Hu, J.; Lazar, A. J.; Tsujikawa, T.; Diab, A.; Tawbi, H.; Glitza, I. C.; Hwu, W. J.; Patel, S. P.; Woodman, S. E.; Amaria, R. N.; Davies, M. A.; Gershenwald, J. E.; Hwu, P.; Lee, J. E.; Zhang, J.; Coussens, Lisa; Cooper, Z. A.; Futreal, P. A.; Daniel, C. R.; Ajami, N. J.; Petrosino, J. F.; Tetzlaff, M. T.; Sharma, P.; Allison, J. P.; Jenq, R. R.; Wargo, J. A.

In: Science, Vol. 359, No. 6371, 05.01.2018, p. 97-103.

Research output: Contribution to journalArticle

Gopalakrishnan, V, Spencer, CN, Nezi, L, Reuben, A, Andrews, MC, Karpinets, TV, Prieto, PA, Vicente, D, Hoffman, K, Wei, SC, Cogdill, AP, Zhao, L, Hudgens, CW, Hutchinson, DS, Manzo, T, Petaccia De Macedo, M, Cotechini, T, Kumar, T, Chen, WS, Reddy, SM, Szczepaniak Sloane, R, Galloway-Pena, J, Jiang, H, Chen, PL, Shpall, EJ, Rezvani, K, Alousi, AM, Chemaly, RF, Shelburne, S, Vence, LM, Okhuysen, PC, Jensen, VB, Swennes, AG, McAllister, F, Marcelo Riquelme Sanchez, E, Zhang, Y, Le Chatelier, E, Zitvogel, L, Pons, N, Austin-Breneman, JL, Haydu, LE, Burton, EM, Gardner, JM, Sirmans, E, Hu, J, Lazar, AJ, Tsujikawa, T, Diab, A, Tawbi, H, Glitza, IC, Hwu, WJ, Patel, SP, Woodman, SE, Amaria, RN, Davies, MA, Gershenwald, JE, Hwu, P, Lee, JE, Zhang, J, Coussens, L, Cooper, ZA, Futreal, PA, Daniel, CR, Ajami, NJ, Petrosino, JF, Tetzlaff, MT, Sharma, P, Allison, JP, Jenq, RR & Wargo, JA 2018, 'Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients', Science, vol. 359, no. 6371, pp. 97-103. https://doi.org/10.1126/science.aan4236
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103. https://doi.org/10.1126/science.aan4236
Gopalakrishnan, V. ; Spencer, C. N. ; Nezi, L. ; Reuben, A. ; Andrews, M. C. ; Karpinets, T. V. ; Prieto, P. A. ; Vicente, D. ; Hoffman, K. ; Wei, S. C. ; Cogdill, A. P. ; Zhao, L. ; Hudgens, C. W. ; Hutchinson, D. S. ; Manzo, T. ; Petaccia De Macedo, M. ; Cotechini, T. ; Kumar, T. ; Chen, W. S. ; Reddy, S. M. ; Szczepaniak Sloane, R. ; Galloway-Pena, J. ; Jiang, H. ; Chen, P. L. ; Shpall, E. J. ; Rezvani, K. ; Alousi, A. M. ; Chemaly, R. F. ; Shelburne, S. ; Vence, L. M. ; Okhuysen, P. C. ; Jensen, V. B. ; Swennes, A. G. ; McAllister, F. ; Marcelo Riquelme Sanchez, E. ; Zhang, Y. ; Le Chatelier, E. ; Zitvogel, L. ; Pons, N. ; Austin-Breneman, J. L. ; Haydu, L. E. ; Burton, E. M. ; Gardner, J. M. ; Sirmans, E. ; Hu, J. ; Lazar, A. J. ; Tsujikawa, T. ; Diab, A. ; Tawbi, H. ; Glitza, I. C. ; Hwu, W. J. ; Patel, S. P. ; Woodman, S. E. ; Amaria, R. N. ; Davies, M. A. ; Gershenwald, J. E. ; Hwu, P. ; Lee, J. E. ; Zhang, J. ; Coussens, Lisa ; Cooper, Z. A. ; Futreal, P. A. ; Daniel, C. R. ; Ajami, N. J. ; Petrosino, J. F. ; Tetzlaff, M. T. ; Sharma, P. ; Allison, J. P. ; Jenq, R. R. ; Wargo, J. A. / Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. In: Science. 2018 ; Vol. 359, No. 6371. pp. 97-103.
@article{de9d622a28aa4ac7bb422294f41fdbcf,
title = "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients",
abstract = "Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.",
author = "V. Gopalakrishnan and Spencer, {C. N.} and L. Nezi and A. Reuben and Andrews, {M. C.} and Karpinets, {T. V.} and Prieto, {P. A.} and D. Vicente and K. Hoffman and Wei, {S. C.} and Cogdill, {A. P.} and L. Zhao and Hudgens, {C. W.} and Hutchinson, {D. S.} and T. Manzo and {Petaccia De Macedo}, M. and T. Cotechini and T. Kumar and Chen, {W. S.} and Reddy, {S. M.} and {Szczepaniak Sloane}, R. and J. Galloway-Pena and H. Jiang and Chen, {P. L.} and Shpall, {E. J.} and K. Rezvani and Alousi, {A. M.} and Chemaly, {R. F.} and S. Shelburne and Vence, {L. M.} and Okhuysen, {P. C.} and Jensen, {V. B.} and Swennes, {A. G.} and F. McAllister and {Marcelo Riquelme Sanchez}, E. and Y. Zhang and {Le Chatelier}, E. and L. Zitvogel and N. Pons and Austin-Breneman, {J. L.} and Haydu, {L. E.} and Burton, {E. M.} and Gardner, {J. M.} and E. Sirmans and J. Hu and Lazar, {A. J.} and T. Tsujikawa and A. Diab and H. Tawbi and Glitza, {I. C.} and Hwu, {W. J.} and Patel, {S. P.} and Woodman, {S. E.} and Amaria, {R. N.} and Davies, {M. A.} and Gershenwald, {J. E.} and P. Hwu and Lee, {J. E.} and J. Zhang and Lisa Coussens and Cooper, {Z. A.} and Futreal, {P. A.} and Daniel, {C. R.} and Ajami, {N. J.} and Petrosino, {J. F.} and Tetzlaff, {M. T.} and P. Sharma and Allison, {J. P.} and Jenq, {R. R.} and Wargo, {J. A.}",
year = "2018",
month = "1",
day = "5",
doi = "10.1126/science.aan4236",
language = "English (US)",
volume = "359",
pages = "97--103",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6371",

}

TY - JOUR

T1 - Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

AU - Gopalakrishnan, V.

AU - Spencer, C. N.

AU - Nezi, L.

AU - Reuben, A.

AU - Andrews, M. C.

AU - Karpinets, T. V.

AU - Prieto, P. A.

AU - Vicente, D.

AU - Hoffman, K.

AU - Wei, S. C.

AU - Cogdill, A. P.

AU - Zhao, L.

AU - Hudgens, C. W.

AU - Hutchinson, D. S.

AU - Manzo, T.

AU - Petaccia De Macedo, M.

AU - Cotechini, T.

AU - Kumar, T.

AU - Chen, W. S.

AU - Reddy, S. M.

AU - Szczepaniak Sloane, R.

AU - Galloway-Pena, J.

AU - Jiang, H.

AU - Chen, P. L.

AU - Shpall, E. J.

AU - Rezvani, K.

AU - Alousi, A. M.

AU - Chemaly, R. F.

AU - Shelburne, S.

AU - Vence, L. M.

AU - Okhuysen, P. C.

AU - Jensen, V. B.

AU - Swennes, A. G.

AU - McAllister, F.

AU - Marcelo Riquelme Sanchez, E.

AU - Zhang, Y.

AU - Le Chatelier, E.

AU - Zitvogel, L.

AU - Pons, N.

AU - Austin-Breneman, J. L.

AU - Haydu, L. E.

AU - Burton, E. M.

AU - Gardner, J. M.

AU - Sirmans, E.

AU - Hu, J.

AU - Lazar, A. J.

AU - Tsujikawa, T.

AU - Diab, A.

AU - Tawbi, H.

AU - Glitza, I. C.

AU - Hwu, W. J.

AU - Patel, S. P.

AU - Woodman, S. E.

AU - Amaria, R. N.

AU - Davies, M. A.

AU - Gershenwald, J. E.

AU - Hwu, P.

AU - Lee, J. E.

AU - Zhang, J.

AU - Coussens, Lisa

AU - Cooper, Z. A.

AU - Futreal, P. A.

AU - Daniel, C. R.

AU - Ajami, N. J.

AU - Petrosino, J. F.

AU - Tetzlaff, M. T.

AU - Sharma, P.

AU - Allison, J. P.

AU - Jenq, R. R.

AU - Wargo, J. A.

PY - 2018/1/5

Y1 - 2018/1/5

N2 - Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.

AB - Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85033587326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033587326&partnerID=8YFLogxK

U2 - 10.1126/science.aan4236

DO - 10.1126/science.aan4236

M3 - Article

VL - 359

SP - 97

EP - 103

JO - Science

JF - Science

SN - 0036-8075

IS - 6371

ER -